Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD
13.98 -0.29 (-2.03%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap581.73M
Revenue (ttm)n/a
Net Income (ttm)-20.91M
Shares Out41.61M
EPS (ttm)-1.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume114,382
Open14.45
Previous Close14.27
Day's Range13.78 - 14.96
52-Week Range13.79 - 37.99
Betan/a
AnalystsStrong Buy
Price Target35.00 (+150.4%)
Earnings Daten/a

About JANX

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and ...

IndustryBiotechnology
IPO DateJun 11, 2021
Employees28
Stock ExchangeNASDAQ
Ticker SymbolJANX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 150.36% from the latest price.

Price Target
$35.00
(150.36% upside)
Analyst Consensus: Strong Buy

News

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...

2 weeks ago - Business Wire

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...

2 months ago - Business Wire

Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...

2 months ago - Business Wire

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...

4 months ago - Business Wire

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...

4 months ago - Business Wire

Janux Therapeutics Reports Second Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today re...

5 months ago - Business Wire

Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Shahram Salek...

6 months ago - Business Wire

Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase...

LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previo...

7 months ago - Business Wire

Merck Partners With Newly Public Cancer Biotech

The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).

Other symbols:MRK
7 months ago - GuruFocus

Janux Therapeutics stock opens at double the upsized IPO's pricing

Janux Therapeutics Inc. received a bullish reception on its Wall Street debut, as shares of the California-based biotechnology company developing cancer treatments opened at double the upsized initial p...

7 months ago - Market Watch